Marinus Pharmaceuticals Inc (MRNS)
1.17
-0.06
(-4.88%)
USD |
NASDAQ |
Jun 28, 16:00
1.17
0.00 (0.00%)
After-Hours: 20:00
Marinus Pharmaceuticals Research and Development Expense (Annual): 99.39M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 99.39M |
| December 31, 2022 | 79.91M |
| December 31, 2021 | 73.52M |
| December 31, 2020 | 51.11M |
| December 31, 2019 | 42.97M |
| December 31, 2018 | 28.39M |
| Date | Value |
|---|---|
| December 31, 2017 | 12.38M |
| December 31, 2016 | 22.00M |
| December 31, 2015 | 18.92M |
| December 31, 2014 | 8.69M |
| December 31, 2013 | 4.15M |
| December 31, 2012 | 0.8456M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
42.97M
Minimum
2019
99.39M
Maximum
2023
69.38M
Average
73.52M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Arcutis Biotherapeutics Inc | 110.58M |
| Heron Therapeutics Inc | 55.90M |
| Pfizer Inc | 10.68B |
| Gritstone Bio Inc | 127.18M |
| Actinium Pharmaceuticals Inc | 38.67M |